Table 1.

Association of bypass signaling activation and HER2 expression status

HER2 IHC status
No. of patients (%)Negative (0–1+)Positive (2+–3+)TotalP
EGFR
 Absent46 (36.2)1 (3.7)47 (30.5)<0.0001a
 Present81 (63.8)26 (96.3)107 (69.5)
p-EGFR
 Absent83 (65.4)2 (7.4)85 (55.2)<0.0001a
 Present44 (34.6)25 (92.6)69 (44.8)
HER3
 Absent53 (41.7)1 (3.7)54 (35.1)<0.0001a
 Present74 (58.3)26 (96.3)100 (64.9)
p-HER3
 Absent77 (60.6)5 (18.5)82 (53.2)<0.0001
 Present50 (39.4)22 (81.5)72 (46.8)
MET
 Absent81 (63.8)5 (18.5)86 (55.8)<0.0001
 Present46 (36.2)22 (81.5)68 (44.2)
p-MET
 Absent95 (74.8)8 (29.6)103 (66.9)<0.0001
 Present32 (25.2)19 (70.4)51 (33.1)
IGFR
 Absent28 (22.0)6 (22.2)34 (22.1)0.984
 Present99 (78.0)21 (77.8)120 (77.9)
p-IGFR
 Absent62 (48.8)6 (22.2)68 (44.2)0.011
 Present65 (51.2)21 (77.8)86 (55.8)
PTEN
 Negative59 (46.5)1 (3.7)60 (39.0)<0.0001a
 Positive68 (53.5)26 (96.3)94 (61.0)
  • aTwenty-five percent of all cells had an expected count <5; the Fisher exact test. The Pearson χ2 test for all other analyses.